Outlook Therapeutics has won FDA approval for LYTENAVA (bevacizumab-vikg), making it the first and only ophthalmic bevacizumab formulation approved for treating wet AMD in the United States and a potential new standard of care developed specifically for the eye. The approval follows a lengthy regulatory history and positions LYTENAVA with anticipated market exclusivity under the BPCIA while signaling a major milestone for retina care.
